Adamis Pharmaceuticals Corp (ADMP.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|71||2014||Independent Chairman of the Board|
|71||2009||President, Chief Executive Officer, Director|
|54||2009||Chief Financial Officer, Vice President - Finance|
|44||2010||Senior Vice President - Corporate Development, Director|
|62||2009||Vice President - Operations|
- BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans
- BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application
- BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses
- BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
- BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi